Fig. 2From: CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthmaStudy design. *For participants who cannot visit the study site at week 28 owing to the COVID-19 pandemic, treatment can be extended to up to 52 weeks until they are able to visit the study site. Q4W, every 4 weeks. SC, subcutaneousBack to article page